Vertex Pharmaceuticals main competitors are Novartis, Boehringer Ingelheim, and Cytel.

Competitor Summary. See how Vertex Pharmaceuticals compares to its main competitors:

  • Johnson & Johnson has the most employees (134,500).
  • Employees at Novartis earn more than most of the competitors, with an average yearly salary of $112,479.
  • The oldest company is U.S. Pharmacopeia, founded in 1820.
Work At Vertex Pharmaceuticals?
Share Your Experience

Vertex Pharmaceuticals vs competitors

Vertex Pharmaceuticals Competitors Jobs

Vertex Pharmaceuticals Jobs openings vs Similar Companies

If you’re looking for a job, here are the jobs openings at Vertex Pharmaceuticals and its competitors.

Vertex Pharmaceuticals Remote Jobs

Vertex Pharmaceuticals salaries vs Competitors

Among Vertex Pharmaceuticals competitors, employees at Novartis earn the most with an average yearly salary of $112,479.

Compare Vertex Pharmaceuticals Salaries VS Competitors

CompanyAverage SalaryHourly SalarySalary Score
Vertex Pharmaceuticals
Johnson & Johnson
Gilead Sciences

Compare Vertex Pharmaceuticals Job Title Salaries VS Competitors

CompanyHighest SalaryHourly Salary
Vertex Pharmaceuticals
U.S. Pharmacopeia
Alexion Pharmaceuticals
Sanofi Genzyme
Hoffmann-LA Roche Inc
Parexel International
Pharmaceutical Research Associates, Inc.
Axio Research
Gilead Sciences
Bristol-Myers Squibb
Eli Lilly and Company
Boehringer Ingelheim

Vertex Pharmaceuticals Jobs

Vertex Pharmaceuticals demographics vs competitors

Compare Gender At Vertex Pharmaceuticals Vs Competitors

Job TitleMaleFemale
Eli Lilly and Company53%47%
Bristol-Myers Squibb53%47%
Vertex Pharmaceuticals56%44%
Gilead Sciences56%44%
Alexion Pharmaceuticals57%43%

Compare Race At Vertex Pharmaceuticals Vs Competitors

CompanyWhiteHispanic or LatinoBlack or African AmericanAsianUnknownDiversity Score

Vertex Pharmaceuticals REVENUE Vs Competitors

Vertex Pharmaceuticals revenue is $8.9B. Among it's competitors, the company with the highest revenue is Pfizer, $100.3B . The company with the lowest revenue is Axio Research, $5.4M.
  • Vertex Pharmaceuticals
  • Alexion Pharmaceuticals
  • Amgen
  • Bristol-Myers Squibb

Vertex Pharmaceuticals And Similar Companies CEOs


Marc’s career in pharmaceuticals, which has included periods with Roussel Uclaf, Hoechst Marion Roussel and GlaxoSmithKline (GSK), has given him extensive industry experience, including finance and accounting; corporate strategy and planning; research and development; sales and marketing; business reorganisation; and business development. Marc is a qualified accountant and joined AstraZeneca in 2013, serving as Executive Vice-President, GPPS from June to October 2013. Prior to that, he served as Global Head of Rare Diseases at GSK and (concurrently) Chairman, GSK Japan. He holds an MBA from HEC, Paris and a Bachelor of Law degree from Paris University.

Robert A. Bradway

Robert A. Bradway is an American businessman. He is the chairman and chief executive officer of Amgen.

Giovanni Caforio
Bristol-Myers Squibb

Dr. Caforio has been our Chief Executive Officer since May 2015. He was our Chief Executive Officer Designate from January to May 2015, our Chief Operating Officer from June 2014 to May 2015, and he served as Executive Vice President and Chief Commercial Officer from November 2013 to June 2014. From October 2011 to November 2013, he served as President, U.S. He held the position of Senior Vice President, Global Commercialization and Immunology from May 2010 to October 2011. Prior to that, he served as Senior Vice President, Oncology, U.S. and Global Commercialization from March 2009 to May 2010. From January 2007 to March 2009 he served as Senior Vice President, U.S. Oncology and from May 2004 to January 2007, he served as Senior Vice President, European Marketing and Brand Commercialization. Dr. Caforio is a member of the Board of Trustees of Hun School of Princeton and a member of the Business Roundtable, CEO Roundtable on Cancer and the Pharmaceutical Research and Manufacturers of America (PhRMA) and The Prium.

David A. Ricks
Eli Lilly and Company

I'm the chairman and CEO of Eli Lilly and Company, after holding management roles in the U.S., Canada and China, as well as running Lilly’s largest business unit. Before I joined Lilly in 1996, I worked as an account rep at IBM. I'm on the board of Adobe, and I'm chairman of the board of the Pharmaceutical Research and Manufacturers of America (PhRMA). I also serve on the board of the Central Indiana Corporate Partnership. I'm a member of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) CEO Steering Committee, The Business Council, Business Roundtable and the National Council for Expanding American Innovation (NCEAI). I serve on the Riley Children’s Foundation’s board of governors. I am a digital media spokesperson for Lilly and discuss topics related to our company, our business and the health care environment. We operate in a highly regulated environment, and only designated employees can discuss our products or pipeline. If you need information about our products or have questions or concerns, please visit these resources:

Daniel O’Day
Gilead Sciences

Hervé Hoppenot

Hervé Hoppenot joined Incyte in 2014 as President and Chief Executive Officer, and was appointed Chairman of the Board of Directors in 2015. During Mr. Hoppenot’s tenure, the Company has tripled the number of clinical candidates in its portfolio, expanding beyond oncology to include research and development in inflammation & autoimmunity. Under his leadership, revenue has increased by over 400 percent, which includes the addition of two new revenue streams; and, with a goal to deliver medicines to patients worldwide, the Company has expanded geographically beyond the U.S. to include operations in 10 EU countries and Japan. Prior to joining Incyte, Mr. Hoppenot was the President of Novartis Oncology. Prior to joining Novartis in 2003, Mr. Hoppenot started his career in 1983 with Rhone Poulenc, later known as Aventis, where he served in several senior roles of increasing responsibility, including Vice President of Oncology and Head of the U.S. Oncology business unit. Mr. Hoppenot holds a diploma from ESSEC Business School.

Joaquin Duato
Johnson & Johnson

Robert M. Davis

Robert M. Davis is corporate vice president and president of Baxter's Medical Products business. In this position, Davis oversees a range of products used in the delivery of fluids and drugs to patients, and in the treatment of end-stage kidney disease. Davis took on his current role in October 2010. Prior to this role, Davis served as corporate vice president and president of Baxter's Renal business. He served as corporate vice president and chief financial officer from 2006 through May 2010, and as treasurer from 2004 through 2006. Davis joined Baxter as treasurer in November 2004 from Eli Lilly and Company, where he served in numerous positions of increasing responsibility over 14 years. Davis currently serves on the Board of Trustees for Rush University Medical Center and also serves as a member of the Finance Committee. He also is a member of the Board of Directors of AdvaMed.

Jamie MacDonald
Parexel International

Jamie Macdonald is Chief Executive Officer of Parexel. He has nearly 25 years of experience in leading global biopharmaceutical services companies. Prior to joining Parexel, Mr. Macdonald served as CEO of INC Research, now known as Syneos Health, from January 2013 through September 2016, where he led the company through a successful Initial Public Offering in 2014. Mr. Macdonald also served as INC’s Chief Operating Officer from July 2011 through December 2012, and previously held several leadership positions in the biopharmaceutical services industry, including Senior Vice President and Head of Global Project Management at Quintiles, now known as IQVIA. Prior to this, he held various senior operational and finance roles at Quintiles. He has previously served on the Board of Directors for the Association of Clinical Research Organizations (ACRO) and as its Chairman in 2015. Mr. Macdonald’s recent experience also includes serving as Chairman of the Board for Certara, a drug development consultancy with solutions spanning discovery, preclinical and clinical drug development, from 2017 to 2018. Mr. Macdonald began his career in the pharmaceutical industry with Syntex Corporation (acquired by Roche Holdings, Inc.). A native of Scotland, he holds a B.A. in Economics from Heriot-Watt University in Edinburgh, Scotland and is a qualified Chartered Management Accountant (ACMA).

Dr. Albert Bourla

Albert Bourla (Greek: Άλμπερτ Μπουρλά, born) is a Greek veterinarian and the chairman and chief executive officer of Pfizer, an American pharmaceutical company. He joined the company in 1993 and has held several executive roles across Pfizer's divisions. Prior to becoming chief executive officer, Bourla served as chief operating officer.